卡巴他赛联合阿比特龙治疗多西他赛和阿比特龙治疗后进展的转移性去势抵抗性前列腺癌的I/II期试验
这项开放标签I/II期试验评估卡巴他赛联合阿比特龙在多西他赛后进展(I期)及多西他赛和阿比特龙后进展(II期)的转移性去势抵抗性前列腺癌患者中的抗肿瘤活性和耐受性。I期确定最大耐受剂量为两药获批剂量,未发现剂量限制性毒性;II期26例可评估患者中12例(46%)达PSA应答,中位PSA无进展生存6.9个月。
要点
- I期9例可评估患者未发现剂量限制性毒性,最大耐受剂量为卡巴他赛25 mg/m2每3周联合阿比特龙1000 mg每日一次。
- II期26例可评估患者中12例(46%;95%CI 26.6-66.6%)达到PSA应答。
- 中位PSA无进展生存6.9个月(95%CI 4.1-10.3个月),14例可测量病灶患者中3例(21%)达部分缓解。
核心结论
- 卡巴他赛联合阿比特龙具有可管理的安全性特征,并在既往接受多西他赛和阿比特龙治疗的患者中显示出抗肿瘤活性。
研究设计与样本
- 开放标签I/II期试验(NCT01511536),I期纳入10例患者(9例可评估),II期27例患者接受卡巴他赛联合阿比特龙联合泼尼松5 mg每日两次治疗。
主要发现
- I期未发现剂量限制性毒性,最大耐受剂量为卡巴他赛25 mg/m2每3周联合阿比特龙1000 mg每日一次,每日阿比特龙治疗未影响卡巴他赛清除率。
- II期卡巴他赛中位给药周期数为7(范围1-28),3-4级治疗中出现的不良事件包括乏力(5例;14%)、中性粒细胞减少(5例;14%)和腹泻(3例;8%)。
- 9例患者(24%)需要降低卡巴他赛剂量。
- 26例可评估患者中12例达到PSA应答(46%;95%CI 26.6-66.6%),中位PSA无进展生存6.9个月(95%CI 4.1-10.3个月)。
- 14例基线有可测量病灶的患者中3例(21%)按实体瘤疗效评价标准达到部分缓解。
关键数值与推荐
- PSA应答定义为PSA较基线下降≥50%且至少3周后确认。
- 最大耐受剂量确定为卡巴他赛25 mg/m2每3周联合阿比特龙1000 mg每日一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label phase I/II trial of cabazitaxel plus abiraterone to assess the antitumor activity and tolerability in patients with progressive mCRPC after docetaxel (phase I), and after docetaxel and abiraterone (phase II) (NCT01511536). PATIENTS AND METHODS: The primary objectives were to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cabazitaxel plus abiraterone (phase I), and the prostate-specific antigen (PSA) response defined as a ≥ 50% decrease confirmed ≥3 weeks later with this combination (phase II). RESULTS: Ten patients were enrolled in the phase I component; nine were evaluable. No DLTs were identified. The MTD was established as the approved doses for both drugs (cabazitaxel 25 mg/m2 every 3 weeks and abiraterone 1000 mg once daily). Daily abiraterone treatment did not impact on cabazitaxel clearance. Twenty-seven patients received cabazitaxel plus abiraterone plus prednisone (5 mg twice daily) in phase II. The median number of cycles administered (cabazitaxel) was seven (range: 1-28). Grade 3-4 treatment-emergent adverse events included asthenia (in 5 patients; 14%), neutropenia (in 5 patients; 14%) and diarrhea (in 3 patients; 8%). Nine patients (24%) required dose reductions of cabazitaxel. Of 26 evaluable patients, 12 achieved a PSA response [46%; 95% confidence interval (CI): 26.6-66.6%]. Median PSA-progression-free survival was 6.9 months (95% CI: 4.1-10.3 months). Of 14 patients with measurable disease at baseline, 3 (21%) achieved a partial response per response evaluation criteria in solid tumors. CONCLUSIONS: The combination of cabazitaxel and abiraterone has a manageable safety profile and shows antitumor activity in patients previously treated with docetaxel and abiraterone.
引用
- Massard C, Mateo J, Loriot Y, et al. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Ann Oncol. 2017. PMID: 28039155. doi:10.1093/annonc/mdw441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。